Reify Health scores $220M series C to speed up trial recruitment, enrollment
August 19, 2021
The COVID-19 pandemic emphasized the need for quicker clinical trial enrollment and more decentralized studies to assuage safety concerns. Those long-lasting impacts have given investors the confidence to funnel $220 million into Reify Health.
The series C is more than seven times the size of Reify’s $30 million series B, raised almost exactly one year ago. The massive investment gives Boston-based Reify a $2.2 billion valuation, which is more than double the valuation of hybrid trial company Science 37 through its planned special purpose acquisition merger.
Clinical trial software and research organizations can be the limiting factor when it comes to speeding up recruitment and enrollment, so Reify felt a responsibility to scale up its products with another round of financing, said CEO Ralph Passarella in an interview with Fierce Biotech.
Read the source article at fiercebiotech.com
2021-08-09 17:36:39